Replies to post #813728 on NorthWest Biotherapeutics Inc (NWBO)

[VikingInvest]

It doesn't.

[Investor082]

He is a liar. As long as folks like him exist here, you can bet LP will continue to disappoint. They will come up with more silly excuses for dilution in pennies throughout 2026 and 2027. I expect them to run out of shares again around mid to late 2027.

[manibiotech]

Pure speculation , based on no documentation or evidence . 

[Doc logic]

barnstormer,

I believe that transition from artisan to Flaskworks must be accounted for before approval of artisan and only is doable in a reasonable time frame with a final GMP Flaskworks model chosen and ready to move into final on site validation. Others believe this is a separate issue but then have no reasonable explanation for such a long delay to approval for a manufacturing method that has been around for a very long time which will not be able to keep up with demand from all directions once approval is granted.
Approval does not guarantee profitability either so getting Flaskworks up and running asap after approval is crucial for business success and the Class C buildout with no further plans for Class B clean rooms tells the story about meeting initial demand starting with artisan that is expected to transition quickly to Flaskworks.
Whether anyone puts emphasis on regulators wanting Flaskworks or NWBO needs to transition to be profitable, the preparation is the same. To me the delay in approval is best explained by regulator desire to have Flaskworks ready ASAP and NICE reimbursement rate being able to keep the pressure on for Flaskworks advancement. Nice has not received what they need from NWBO for reimbursement that we know of yet and if approval was based only on artisan that should have been in already. Seems reimbursement rate can only really help when Flaskworks is ready; ). Best wishes.

[HappyLibrarian]

Doc, maybe I'm misreading your post, but why would artisan approval depend on a Flaskworks GMP final version?

It is getting harder and harder to find a positive explanation for this delay so the narrative that approval is tied to automation is a crucial way to deal with the cognitive dissonance between the wait time consistent with the idea that TLD was a slam dunk / the UK is friendly to NWBO vs what a 2 year wait for approval suggests about the harsh reality behind the scenes.

Trying to keep inserting manufacturing into the process also is meant to imply that we will somehow move faster after approval because of everything done on manufacturing. That is probably wishful thinking - with NWBO a long wait now does not buy immunity from even longer waits that pile on each other.

If you don’t like my response, ask yourself this:

How many shareholders on the dark day of October 5, 2020 would have predicted that we would still be debating this kind of crap and would still be a pre-revenue biotech valued as less than 50 cents a share in Q1 2026.